SCHEMBL1385236

SCHEMBL1385236

OCCCNc1nccc(-c2cc3cn(CCCO)nc3nc2-c2ccc(F)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.43
DYRK1B Q9Y463 2/20 0.40
MAPK10 P53779 2/20 0.39
CSNK1D P48730 2/20 0.38
CSNK1E P49674 1/20 0.38
RAF1 P04049 1/20 0.38
BRAF P15056 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PIK3C3 Q8NEB9 1/20 0.37
MKNK1 Q9BUB5 1/20 0.37
DYRK3 O43781 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
MATK P42679 1/20 0.37
FRK P42685 1/20 0.37
MAPK9 P45984 1/20 0.37
CSNK1A1 P48729 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29652653 0.94 MAPK14 (0.47) MAPK14DYRK1BMAPK10CSNK1DCSNK1E
SCHEMBL1386383 0.89 PRKD3 (0.47) MAPK14MAPK10CSNK1DPIK3C3MKNK1
SCHEMBL1385433 0.87 MAPK14 (0.45) MAPK14DYRK1BMAPK10CSNK1DCSNK1E
SCHEMBL1385005 0.84 MAPK14 (0.44) MAPK14CSNK1DCSNK1EMAP4K4MAPK9
SCHEMBL1387079 0.83 PRKD3 (0.49) MAPK14MAPK10CSNK1DMKNK1PRKD3
SCHEMBL1386435 0.81 PTGS2 (0.40) MAPK14CSNK1DCSNK1EMAP4K4MAPK9
SCHEMBL29652643 0.79 MAPK14 (0.47) MAPK14MAPK10CSNK1DCSNK1EMKNK1
SCHEMBL29894134 0.79 MAPK14 (0.50) MAPK14MAPK10CSNK1DCSNK1ERAF1
SCHEMBL1387131 0.79 MAPK14 (0.46) MAPK14CSNK1DCSNK1EMAP4K4FRK
SCHEMBL29652656 0.78 PRKD3 (0.49) MAPK14MAPK10CSNK1DMKNK1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP claimed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885DYRK1B 1563/4885MAPK10 37/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885DYRK1B 2158/4885MAPK10 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.